News & Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. For the sole purpose of achieving an equal balance of membership among the three classes of the Board of Directors (the “ Board ”) of Solid Biosciences Inc. (the “ Company ”), effective at 4:00 p.m., Eastern Time, on April 10, 2026, Ilan Ganot, a member of the Board who was serving in Class III (which class will be up for election at the Company’s…

Other Events. SGT-003 Interim Clinical Update for INSPIRE DUCHENNE On March 11, 2026, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy (“Duchenne”) at a dose level of 1E14vg/kg. SGT-003 is administered as a one-time intravenous infusion. The inte…

Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Shares and the Pre-Funded Warrants will be exempt from registration under Section 4(a)(2) of the Securities Act. The Shares and Pre-Funded Warrants have not been registered under the Securities Act or any state securities laws, and the Shares and Pre-Funded Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per shar…

Results of Operations and Financial Condition. Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company expects to report cash, cash equivalents and available-for-sale securities of approximately $187.9 million as of December 31, 2025. The estimated cash, cash equivalents and available-for-sale securities figure is preliminary and unaudited, represents management’s estimate as of the date of this report, is s…

Other Events. Based upon the Company’s current operating plan, the Company estimates that the net proceeds from the Private Placement, together with the Company’s existing cash, cash equivalents and available-for-sale securities, will enable the Company to fund its operating expenses and capital expenditure requirements into the first half of 2028. The Company expects to use the net proceeds from the Private Placement, together with its existing cash, cash equivalents and available-for-sale s…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Other Events. On May 15, 2025, Solid Biosciences Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-277871) that was originally filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2024 and was declared effective by the SEC on May 17, 2024 (the “Registration Statement”), relating to the offer and sale of a total of up to $85.0 million of shares of the Compan…

Entry Into a Material Definitive Agreement. On February 18, 2025, Solid Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of 35,739,810 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Comm…

Other Events. On February 18, 2025, the Company issued a press release announcing the pricing of the offering. A copy of the press release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, such as those, among others, relating to the expecte…

Other Events. On February 18, 2025, Solid Biosciences Inc. (the “Company”) issued a press release announcing the pricing of a $200.0 million underwritten offering, which is expected to close on February 19, 2025. Based upon the Company’s current operating plan, the Company estimates that the net proceeds from the offering, together with the Company’s existing cash, cash equivalents and available-for-sale securities, will enable the Company to fund its operating expenses and capital expenditur…

Results of Operations and Financial Condition. The information disclosed under the heading “Cash, Cash Equivalents and Available-for-Sale Securities as of December 31, 2024” under